Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

NCT02594163 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision based on portfolio prioritization

Conditions

Diffuse Large B-cell Lymphoma Refractory
Follicular B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG: Brentuximab Vedotin
DRUG: Rituximab
DRUG: Bendamustine

Sponsor

Seagen Inc.